Cantor Fitzgerald Initiates Coverage of Bioventus (BVS) with an Overweight Rating

Bioventus Inc. (NASDAQ:BVS) is one of the best undervalued medical device stocks to buy now. On July 7, Cantor Fitzgerald analyst Ross Osborn initiated coverage of Bioventus Inc. (NASDAQ:BVS) with an Overweight rating and $12 price target.

Tempus AI (TEM) Expands Precision Medicine Capabilities with Deep 6 AI Acquisition

A doctor repairing a foot and ankle injury using the latest sports medicine techniques.

The company reported a 4.3% decline in its worldwide revenue for fiscal Q1 2025 to $123.9 million from $129.5 million in the same period last year. The drop reflects the effects of the previous year’s divestiture of the Advanced Rehabilitation Business.

Bioventus Inc. (NASDAQ:BVS) also reported a 5.0% growth in organic revenue in the quarter, attributed to positive organic growth across all three businesses.

Global revenue in Paint Treatments rose 3.9% to $58.9 million, driven by double-digit growth in demand for Durolane. Durolane is a single-injection hyaluronic acid therapy that targets knee osteoarthritis.

Similarly, Surgical Solutions also underwent a 7.0% growth in global revenue in the quarter to $45.2 million, attributed to double-digit growth from Ultrasonics due to strong capital equipment purchases in the US.

Bioventus Inc. (NASDAQ:BVS) is a medical technology company that develops and commercializes proprietary orthobiologic products to treat musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP.

While we acknowledge the potential of BVS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than XXXX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.